LLY
Eli Lilly and Company
LLY has the edge over RDY overall, supported by stronger fundamentals and stronger modeled upside.
RDY
Dr. Reddy's Laboratories Limited
RDY's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RDY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
RDY's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RDY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $6.94 | -53% |
| Fair | 31x | $11.07 | -25% |
| Current | 41x | $14.73 | — |
| Expensive | 43x | $15.47 | +5% |
Historical ranges are pointers, not guarantees.
RDY has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RDY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for RDY, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RDY on earnings, with more consistent year-over-year improvement.
RDY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.36 | -52% |
| Q2 2026 | $0.42 | -42% |
| Q1 2026 | $0.55 | -24% |
| Q4 2025 | $0.72 | +4.3% |
| Q3 2025 | $0.75 | +10% |
RDY's earnings per share have fallen from their peak: $0.36 over the past year, against $0.75 in late 2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RDY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RDY on profitability, with a higher operating margin.
RDY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $923.8M | -1.7% |
| Q2 2026 | $866.1M | -5% |
| Q1 2026 | $814.3M | -10% |
| Q4 2025 | $931M | +4.4% |
| Q3 2025 | $939.3M | +9.8% |
| Q2 2025 | $911.6M | +11% |
| Q1 2025 | $907.4M | +20% |
| Q4 2024 | $891.7M | +16% |
RDY's revenue grew through 2024 and has held roughly level since: $924M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -6.2 points |
| Q2 2026 | 3.7% | -17 points |
| Q1 2026 | 0.6% | -20 points |
| Q4 2025 | 16% | -6.1 points |
| Q3 2025 | 20% | -2 points |
| Q2 2025 | 20% | -2.9 points |
| Q1 2025 | 21% | -0.4 points |
| Q4 2024 | 22% | -1.5 points |
RDY's operating margin was 14% last quarter, down 6.2 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RDY on cash flow, with more consistent year-over-year improvement.
RDY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -58% |
| Q2 2026 | -$49.4M | -203% |
| Q1 2026 | $114.7M | 0% |
| Q4 2025 | $38.3M | +$61.7M |
| Q3 2025 | $58M | +286% |
| Q2 2025 | $47.8M | +116% |
| Q1 2025 | $114.7M | +14646% |
| Q4 2024 | -$23.5M | -30999% |
RDY still generates free cash flow, though less than at its 2022 peak: $128M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RDY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RDY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +662K shares |
| 1 year | 0% | +313K shares |
| 3 years | +0.2% | +1.4M shares |
RDY has 833M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $14.8M |
| Q4 2024 | — |
RDY hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RDY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.0x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.4x | Very low |
RDY has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RDY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.4 | Neutral |
| Stochastic | 94.8 | Overbought |
RDY's weekly RSI is 66 (neutral) and its Stochastic is 95 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RDY PE vs Healthcare Sector
| Metric | RDY | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 57% above |
| PE % | 74 | 29 | 45 pts above |
RDY has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
RDY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.4 | 10% above |
| 20 week MA | $12.8 | 15% above |
| 50 week MA | $13.4 | 10% above |
| 100 week MA | $13.8 | 6.8% above |
| 200 week MA | $13.8 | 7% above |
RDY is in an uptrend: it's above all five of its weekly moving averages, and 7% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RDY on returns for 2026, with the stronger performance.
RDY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.12 | $14.1 | +74% |
| 2021 | $14.1 | $12.6 | -11% |
| 2022 | $12.6 | $10.5 | -16% |
| 2023 | $10.5 | $13.9 | +32% |
| 2024 | $13.9 | $15.9 | +14% |
| 2025 | $15.9 | $14.2 | -11% |
| 2026 YTD | $14.2 | $14.7 | +4% |
RDY has finished lower in three of the last six years. It's up 4% so far in 2026.